Last reviewed · How we verify
Ocriplasmin 25µg — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Ocriplasmin 25µg (Ocriplasmin 25µg) — ThromboGenics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ocriplasmin 25µg TARGET | Ocriplasmin 25µg | ThromboGenics | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ocriplasmin 25µg CI watch — RSS
- Ocriplasmin 25µg CI watch — Atom
- Ocriplasmin 25µg CI watch — JSON
- Ocriplasmin 25µg alone — RSS
Cite this brief
Drug Landscape (2026). Ocriplasmin 25µg — Competitive Intelligence Brief. https://druglandscape.com/ci/ocriplasmin-25-g. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab